PCM
EPZM

Piermont Capital Management’s Epizyme, Inc EPZM Stock Holding History

Piermont Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-32,239
Closed -$516K – 270
2015
Q4 		$516K Buy
+32,239
New +$478K 0.16% 141

Other funds holding EPZM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Piermont Capital Management's EPZM Position: Q1 2016 in Review

Piermont Capital Management sold out of Epizyme, Inc (EPZM) in Q1 2016, closing a stake of 32,239 shares — an estimated $516K sold.

Piermont Capital Management first reported a position in EPZM in Q4 2015 and held it in 1 quarter. The position peaked at $516K in Q4 2015. 91 funds tracked by Wall St. Rank hold EPZM as of Q1 2016.

  • Piermont Capital Management reported no remaining Epizyme, Inc position as of Q1 2016 after selling out during the quarter.
  • Piermont Capital Management sold 32,239 Epizyme, Inc shares in Q1 2016, an estimated $516K.
  • Piermont Capital Management first reported a position in Epizyme, Inc in Q4 2015 and held it in 1 quarter.
  • Piermont Capital Management's Epizyme, Inc position peaked at $516K in Q4 2015.
  • 91 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2016.

Based on Piermont Capital Management's 13F filing for Q1 2016, filed 11 May 2016.